MA49971B1 - Vésicules extracellulaires modifiées et leurs utilisations - Google Patents
Vésicules extracellulaires modifiées et leurs utilisationsInfo
- Publication number
- MA49971B1 MA49971B1 MA49971A MA49971A MA49971B1 MA 49971 B1 MA49971 B1 MA 49971B1 MA 49971 A MA49971 A MA 49971A MA 49971 A MA49971 A MA 49971A MA 49971 B1 MA49971 B1 MA 49971B1
- Authority
- MA
- Morocco
- Prior art keywords
- exosomes
- protein
- therapeutic
- present
- luminal surface
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 abstract 10
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835430P | 2019-04-17 | 2019-04-17 | |
| PCT/US2019/033629 WO2020101740A1 (en) | 2018-11-16 | 2019-05-22 | Engineered extracellular vesicles and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49971A MA49971A (fr) | 2020-07-01 |
| MA49971B1 true MA49971B1 (fr) | 2022-01-31 |
Family
ID=70732111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49971A MA49971B1 (fr) | 2019-04-17 | 2019-05-22 | Vésicules extracellulaires modifiées et leurs utilisations |
Country Status (28)
| Country | Link |
|---|---|
| EP (3) | EP4059510B1 (https=) |
| JP (2) | JP7538795B2 (https=) |
| KR (1) | KR20210098473A (https=) |
| CN (2) | CN113286603B (https=) |
| AU (1) | AU2019378591A1 (https=) |
| BR (1) | BR112021009231A2 (https=) |
| CA (1) | CA3119720A1 (https=) |
| CL (1) | CL2021001278A1 (https=) |
| CY (1) | CY1124897T1 (https=) |
| DK (1) | DK3672614T3 (https=) |
| EA (1) | EA202191334A1 (https=) |
| ES (1) | ES2907967T3 (https=) |
| HR (1) | HRP20220020T1 (https=) |
| HU (1) | HUE057300T2 (https=) |
| IL (1) | IL283167A (https=) |
| LT (1) | LT3672614T (https=) |
| MA (1) | MA49971B1 (https=) |
| MD (1) | MD3672614T2 (https=) |
| MX (1) | MX2021005636A (https=) |
| PH (1) | PH12021551088A1 (https=) |
| PL (1) | PL3672614T3 (https=) |
| PT (1) | PT3672614T (https=) |
| RS (1) | RS62863B1 (https=) |
| SG (1) | SG11202104956QA (https=) |
| SI (1) | SI3672614T1 (https=) |
| SM (1) | SMT202200156T1 (https=) |
| TW (2) | TWI846697B (https=) |
| WO (1) | WO2020101740A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111290WA (en) * | 2019-04-17 | 2021-11-29 | Codiak Biosciences Inc | Compositions of exosomes and aav |
| EP3994158A1 (en) | 2019-07-03 | 2022-05-11 | Codiak BioSciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| KR20220070433A (ko) * | 2019-08-14 | 2022-05-31 | 코디악 바이오사이언시즈, 인크. | Stat6을 표적으로 하는 세포외 소포-aso 작제물 |
| CA3147366A1 (en) | 2019-08-14 | 2021-02-18 | Adam T. BOUTIN | Extracellular vesicles with stat3-antisense oligonucleotides |
| CA3147701A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| AU2020330133A1 (en) * | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
| MX2022003570A (es) | 2019-09-25 | 2022-07-11 | Codiak Biosciences Inc | Composiciones de vesícula extracelular. |
| KR20220094221A (ko) | 2019-09-25 | 2022-07-05 | 코디악 바이오사이언시즈, 인크. | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 |
| WO2021062290A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
| WO2021062058A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| KR20210116324A (ko) | 2020-03-12 | 2021-09-27 | 기초과학연구원 | 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법 |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| WO2022032140A2 (en) * | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
| CA3193107A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
| US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
| JP2024506712A (ja) | 2021-02-17 | 2024-02-14 | ロンザ セールス アーゲー | 細胞外ベシクルを負荷する方法 |
| CA3207944A1 (en) * | 2021-02-17 | 2022-08-25 | Ajay Verma | Extracellular vesicle-nlrp3 antagonist |
| KR20230166101A (ko) | 2021-04-01 | 2023-12-06 | 론자 세일즈 아게 | 세포외 소포 조성물 |
| CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
| CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
| KR102788272B1 (ko) * | 2022-05-24 | 2025-04-01 | 주식회사 시프트바이오 | 표면-개질된 세포외 소포체 및 이의 치료학적 용도 |
| WO2024215711A1 (en) * | 2023-04-10 | 2024-10-17 | Wake Forest University Health Sciences | Modified mammalian vesicles and compositions and methods related thereto |
| CN116769718A (zh) * | 2023-04-21 | 2023-09-19 | 南京逸微健华生物科技有限公司 | 一种工程化细胞外囊泡及用途 |
| WO2024226723A1 (en) * | 2023-04-26 | 2024-10-31 | Northwestern University | Active loading of biomolecular cargo into engineered vesicles |
| CN118909084A (zh) * | 2023-05-08 | 2024-11-08 | 天津外泌体科技有限公司 | 细胞外囊泡支架蛋白及其应用 |
| EP4644537A1 (en) | 2024-04-30 | 2025-11-05 | ConvEyXo | Targeted extracellular vesicle |
| WO2025232431A1 (zh) * | 2024-05-08 | 2025-11-13 | 天津外泌体科技有限公司 | 筛选影响细胞外囊泡被摄取的基因的系统和方法 |
| WO2026055342A1 (en) | 2024-09-04 | 2026-03-12 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP2254586B1 (en) * | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| WO2016138525A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2016172598A1 (en) * | 2015-04-22 | 2016-10-27 | The Broad Institute Inc. | Exosomes and uses thereof |
| EP3397264A4 (en) * | 2015-12-30 | 2019-06-05 | The Regents of The University of California | METHOD FOR IMPROVED PREPARATION AND INSULATION OF CELL-DERIVED VESICLES |
| US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
| US20210290556A1 (en) * | 2016-08-22 | 2021-09-23 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| US20200025685A1 (en) * | 2016-12-15 | 2020-01-23 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
| IL272786B2 (en) | 2017-08-25 | 2025-03-01 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
| WO2019099942A1 (en) * | 2017-11-17 | 2019-05-23 | Codiak Biosciences, Inc. | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
| EP3841112A1 (en) * | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
-
2019
- 2019-05-22 SM SM20220156T patent/SMT202200156T1/it unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603B/zh active Active
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro not_active IP Right Cessation
- 2019-05-22 CN CN202510904062.3A patent/CN121102502A/zh active Pending
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/en not_active Ceased
- 2019-05-22 JP JP2021526563A patent/JP7538795B2/ja active Active
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 EP EP21200884.1A patent/EP4059510B1/en active Active
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/en active Active
- 2019-05-22 CA CA3119720A patent/CA3119720A1/en active Pending
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en not_active Abandoned
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko not_active Ceased
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
- 2019-05-22 EP EP25177387.5A patent/EP4628099A3/en active Pending
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-23 TW TW108117910A patent/TWI846697B/zh active
- 2019-05-23 TW TW113122723A patent/TW202438105A/zh unknown
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
-
2024
- 2024-05-10 JP JP2024077013A patent/JP2024097929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49971B1 (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
| Chen et al. | Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities | |
| TWI828673B (zh) | Vista抗原結合分子 | |
| CN113966397A (zh) | 人碳酸酐酶2组合物和用于可调调节的方法 | |
| ES2545609T3 (es) | Composiciones de antagonistas de PD-1 y métodos de uso | |
| JP2018534932A5 (https=) | ||
| MA42073A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
| MA46299B1 (fr) | Molécule de polypeptide à double spécificité améliorée | |
| AU2018226857A1 (en) | Compositions and methods for immunotherapy | |
| MA49513B1 (fr) | Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines | |
| MA41879A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
| JP2020511529A (ja) | 免疫療法のためのｃｄ１９組成物及び方法 | |
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| MA43075A1 (fr) | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers | |
| NZ737046A (en) | Anti-cgrp antibody formulation | |
| MA40713A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
| IL208598A (en) | Linkers of human serum albumin and their constituents, kits and drugs containing them, their use in the preparation of a drug for the treatment of proliferative disease, and a method for their preparation | |
| MA43618A1 (fr) | Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers | |
| RU2018142197A (ru) | Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv | |
| MA43482A1 (fr) | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers | |
| CA3156704A1 (en) | Multi-domain protein vaccine | |
| MX2023015244A (es) | Anticuerpos biespecificos y usos de los mismos. | |
| ZA202302084B (en) | Antibody that binds to vegf-a and ang2 and methods of use | |
| WO2024086617A3 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| MX2025013338A (es) | Composiciones de epcoritamab altamente purificadas |